Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983901 | 0.81 | PIK3CD (0.41) | KMT2AMEN1PIK3CDKDM4ELMNA | |
| SCHEMBL30983821 | 0.81 | PIK3CD (0.40) | KMT2AMEN1PIK3CDLMNACYP1A2 | |
| SCHEMBL30984032 | 0.80 | PIK3CD (0.41) | KMT2AMEN1PIK3CDDAPK1 | |
| SCHEMBL30983950 | 0.79 | PIK3CD (0.40) | KMT2AMEN1PIK3CDKDM4ELMNA | |
| SCHEMBL30983903 | 0.79 | PIK3CD (0.42) | PIK3CDLMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30983784 | 0.78 | PIK3CD (0.40) | KMT2AMEN1PIK3CDDAPK1 | |
| SCHEMBL30983776 | 0.78 | PIK3CD (0.40) | KMT2AMEN1PIK3CDDAPK1 | |
| SCHEMBL30983906 | 0.78 | PIK3CD (0.39) | KMT2AMEN1PIK3CDDAPK1 | |
| SCHEMBL30983817 | 0.78 | CNR1 (0.41) | KMT2APIK3CDALDH1A1LMNACYP1A2 | |
| SCHEMBL30983797 | 0.78 | PIK3CD (0.39) | KMT2AMEN1PIK3CDKDM4EDAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | KMT2A 880/4885RCE1 1822/4885MEN1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.